SWOG clinical trial number
S1801

A Phase II Randomized Study of Adjuvant versus Neoadjuvant Pembrolizumab for Clinically Detectable Stage III-IV High-risk Melanoma.

Open
Phase
II
Accrual
8%
Abbreviated Title
Ph II Ramdomization for Clinically Detectable Stage III-IV High-risk Melanoma
Status Notes
Activation Effective 12/06/2018.
Activated
12/06/2018

Research committees

Melanoma

Treatment

MK-3475

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-7419

VP-16-213(4' Dm Methyl-Epipodophy LL-toxin-B-D Ethylidene Glucoside) in Adults with Metastatic Malignant Melanoma

Research Committee(s)
Melanoma
Activated
08/23/1974
Closed
05/19/1975
Closed
Phase
II
SWOG Clinical Trial Number
SWOG-8049

The Treatment of Resected, Poor Prognosis Malignant Melanoma: Stage I: Surgical Excision Versus Surgical Excision + Vitamin A

Research Committee(s)
Melanoma
Activated
07/29/1981
Closed
03/15/1987
Closed
Phase
III
Published
SWOG Clinical Trial Number
SWOG-8393 (INT-0013)

National Intergroup Protocol for Intermediate Thickness Melanomas 1.0 to 4.0 mm (MEL 82 323)

Research Committee(s)
Melanoma
Activated
07/07/1983
Closed
03/15/1992
Closed
Phase
Published